Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

• Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist.

• Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk's pipeline.

• The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients.

• The Hengrui oral GLP-1/GIP deal and new trial wins tell only part of the Novo Nordisk story. We have also flagged 2 warning signs (1 major) for Novo Nordisk.

For readers assessing treatment-related opportunities and looking for more ideas in adjacent areas, the next place to explore is 88 AI infrastructure stocks .

Novo Nordisk, a pharmaceuticals group with a DKK1.1 trillion market cap, builds its business around researching, developing, manufacturing, and distributing treatments that target chronic conditions. These fresh data points and licensing activity sit squarely in that core focus on metabolic disease and serious disorders such as children's growth issues and hemophilia A.

3 things going right for Novo Nordisk that this headline doesn't cover.

What does the Hengrui oral GLP-1/GIP deal really add for Novo Nordisk?

The Hengrui license hands Novo Nordisk a once weekly oral GLP 1/GIP candidate that complements its injectable and oral GLP 1 work. It sits alongside the Nanexa long acting injectable agreement and the Orbis macrocycle partnership, pointing to a broad push on convenience, dosing flexibility, and cardiometabolic coverage.

Does this cluster of deals and trial wins change the Novo Nordisk Narrative?

These updates lean into the existing Narrative that future returns hinge on obesity pills, new formulations, and adjacent cardiometabolic areas rather than relying only on current GLP 1 injectables. The MASLD and MASH collaboration with Siemens Healthineers, plus weight management data for CagriSema, speak directly to the Narrative catalyst of expanding into new metabolic indications while diversifying beyond Wegovy and Ozempic pricing risk.

See how these catalysts shape Novo Nordisk's path to a DKK310 fair value .

What should investors watch next to judge if this Novo Nordisk push is working?

The clearest marker is whether Novo Nordisk starts attaching concrete timelines and regulatory decisions to these assets, especially the CagriSema NDA decision expected in Q4 2026 and the European Commission rulings on Sogroya and FREHEMGO. Clear progress from phase 1 start for the Hengrui oral GLP 1/GIP candidate will also show how quickly the license translates into a tangible pipeline asset.